INFLIXIMAB INFLIXIMAB (11448M) Supply only until 01/08/2027 infliximab 100 mg injection, 1 vial 11448M Body System: Antineoplastic And Immunomodulating Agents > Immunosuppressants > Immunosuppressants Manner of administration:Injection Public S100 HSD Public Authority Required Restriction Indication: Moderate to severe Crohn disease Treatment phase: Subsequent continuing treatment Quantities & Cost Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $186.16 Max safety net: $25.00 General Patient Charge: $25.00 Available brands Inflectra Ixifi Remicade Remsima Renflexis
